Overview
What is Path Vaccine Solutions?
Path Vaccine Solutions (PVS) is a nonprofit organization dedicated to improving the health of children in low-income countries by expediting the development of cost-effective and efficient vaccines. In 2020, their primary focus was on diarrheal diseases, particularly rotavirus, which is a significant cause of child mortality. PVS continued clinical trials for a nonreplicating rotavirus vaccine candidate, with preparatory activities ongoing at three African sites. They also conducted a case-control study in India to evaluate the effectiveness of a rotavirus vaccine. Additionally, PVS supported clinical trials for vaccine candidates targeting enterotoxigenic Escherichia coli (ETEC) and Shigella, with no licensed vaccines currently available against these pathogens. In 2020, they achieved World Health Organization prequalification for their low-cost pneumococcal conjugate vaccine (Pneumosil), which improved affordability in low- and middle-income countries. They also contributed research on the economic impact of respiratory syncytial virus (RSV) and other acute respiratory infections in infants. In conclusion, PVS works tirelessly to advance vaccine research and development, aiming to provide lifesaving solutions for children in resource-limited settings.
Official website here: www.path.org
Is Path Vaccine Solutions legitimate?
Path Vaccine Solutions is a legitimate nonprofit organization registered as a 501(c)(3) entity. Path Vaccine Solutions submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.path.org
What is the mission statement of Path Vaccine Solutions?
Path Vaccine Solutions, abbreviated as PVS, aims to enhance the health of children in low-resource settings by expediting the development of affordable and effective vaccines. In 2020, PVS continued its battle against diarrheal diseases, which is the second-leading cause of death among children in low-income countries. One of their main focuses was combating rotavirus, a significant contributor to severe diarrhea. They continued the clinical development of a non-replicating rotavirus vaccine candidate, although the phase 3 efficacy study was paused due to the COVID-19 pandemic. Preparatory activities at the three clinical sites in Africa continued throughout the year to ensure readiness for the trial's resumption. Additionally, PVS supported clinical trials and research on vaccine candidates that might provide protection against ETEC and Shigella, the leading bacterial causes of diarrheal illness. However, there are currently no licensed vaccines against either pathogen. In 2020, PVS also made significant strides in the development of a low-cost pneumococcal conjugate vaccine (PCV) called Pneumosil, which became more affordable for low- and middle-income countries.
Official website here: www.path.org
Who is the CEO of Path Vaccine Solutions?
Kelly Priestley is the Chair And President of Path Vaccine Solutions.
Official website here: www.path.org
What is the revenue of Path Vaccine Solutions?
Path Vaccine Solutions's revenue in 2020 was $4,835,308.
Official website here: www.path.org
Who are the executives of Path Vaccine Solutions and what are their salaries?
Here are 8 key members and their salaries:
- Compensation: $0
- Related: $571,940
- Other: $44,054
- Compensation: $0
- Related: $249,057
- Other: $13,602
- Compensation: $0
- Related: $427,937
- Other: $69,391
- Compensation: $0
- Related: $260,514
- Other: $36,826
- Compensation: $0
- Related: $252,897
- Other: $58,226
- Compensation: $0
- Related: $291,278
- Other: $76,724
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Official website here: www.path.org
Where can I find the form 990 for Path Vaccine Solutions?
Path Vaccine Solutions's most recent form 990 was submitted in 2020 and can be accessed here.
Official website here: www.path.org
Learn more at the official website: www.path.org
Mission Statement of Path Vaccine Solutions
Path Vaccine Solutions, or PVS, has a mission aimed at improving the health of children in low-income settings. This organization focuses on accelerating the development of affordable and effective vaccines that can combat diseases that disproportionately affect these communities. In 2020, PVS continued its fight against diarrheal diseases, which is the second leading cause of death among children in low-income countries. One of their primary goals was to combat rotavirus, a major cause of severe diarrhea, by continuing clinical development of a nonreplicating rotavirus vaccine candidate. However, the phase 3 efficacy study was paused throughout 2020 due to the COVID-19 pandemic to protect the health and safety of participating infants and their families. Preparatory activities continued at the three clinical sites in Africa to ensure readiness to restart the trial once conditions allowed.
In addition to rotavirus, PVS also continued conducting studies on vaccine candidates that may provide protection against enterotoxigenic Escherichia coli (ETEC) and Shigella, the leading bacterial causes of diarrheal illness. Currently, there are no licensed vaccines against either pathogen. PVS made significant strides in this area by completing the submission of results from a phase 1 trial of an injectable, subunit ETEC vaccine candidate to the US Food and Drug Administration. They also partially supported the final data analysis for a phase 2B efficacy study of an oral ETEC vaccine candidate in Finnish travelers to Benin, reporting results in March 2020.
PVS's work in 2020 also included achieving World Health Organization prequalification for Pneumosil, a low-cost pneumococcal conjugate vaccine (PCV) developed by PVS and the Serum Institute of India Pvt. Ltd. (SIIPL), which triggered a UNICEF and SIIPL supply agreement in 2020. This agreement, at $2.00 per dose, was more than 30% less expensive than other PCVs, improving affordability for low- and middle-income countries. Pneumosil also received market authorization in India, and a phase 3 clinical trial of Pneumosil in the Gambia also progressed. Overall, Path Vaccine Solutions' mission is to improve the health of children in low-income settings by accelerating the development of affordable and effective vaccines, and their work in 2020 reflected their commitment to this mission.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Path Vaccine Solutions (PVS) is making significant strides in addressing diarrheal diseases—one of the leading causes of mortality among children in low-income countries—particularly through the development of vaccines. In 2020, PVS advanced clinical development for a nonreplicating rotavirus vaccine candidate, which aims to provide better efficacy in resource-limited settings compared to traditional oral vaccines. Though clinical trials were temporarily paused due to the COVID-19 pandemic, preparatory efforts continued.
Additionally, PVS has been evaluating existing rotavirus vaccines, such as Rotasiil, to assess their effectiveness, furthering the understanding of immunization in different contexts. The organization also supports clinical trials for vaccines against enterotoxigenic Escherichia coli (ETEC) and Shigella, pathogens responsible for serious diarrheal illnesses. Their work in 2020 included submitting results for an injectable ETEC vaccine candidate to the US FDA and progressing a Phase 2B study of an oral ETEC vaccine.
A key achievement for PVS was the World Health Organization prequalification of Pneumosil, a low-cost pneumococcal conjugate vaccine developed in collaboration with the Serum Institute of India. This not only enhanced vaccine accessibility at a reduced cost but also led to a supply agreement with UNICEF, improving vaccination options for low- and middle-income countries.
Furthermore, PVS is contributing to the knowledge base around maternal immunization against respiratory syncytial virus (RSV), a significant cause of respiratory infections in infants. This includes publications on the economic impact of RSV and modeling studies that inform vaccine development strategies, aimed at safeguarding the health of vulnerable populations.
Overall, PVS is focused on enhancing vaccine effectiveness and affordability, aiming to significantly improve child health outcomes in low-resource settings.
This information is meant to be a general summary of Path Vaccine Solutions. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2020.
- Investment Income: $975,772
- Gross Receipts: $4,835,308
Assets and Liabilities:
- Total Assets: $0
- Total Liabilities: $0
- Net Assets: $0
Want to help this charity, for free? You can click here to learn more about Give Freely
Organization Details
Founding Year
2006
Phone
(206) 285-3500Principal Officer
Kelly Priestley
Main Address
2201 WESTLAKE AVENUE NO 200, SEATTLE, WA, 98121
Website
www.path.orgNTEE Category
Code: H41 - Medical research
If you are a representative of Path Vaccine Solutions and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.